Latest research on Xolair

A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.

Latest findings

The only FDA-approved anti-IgE therapy is omalizumab (Xolair). [source, 2008]
An analysis of anaphylaxis associated with the use of Xolair (omalizumab) was recently published by the Omalizumab Joint Task Force (OJTF). [source, 2008]
A separate analysis of adverse events reported to the US FDA and to the manufacturers of Xolair (omalizumab) took into account events occurring through December 2006. [source, 2008]
At this point, the most promising therapy, and that nearest marketing, is a monoclonal anti-IgE antibody, omalizumab (Xolair). [source, 2005]
The twenty-fifth antibody in the series, recombinant humanized murine monoclonal antibody E25 (rhuMAb-E25 [E25 for short], omalizumab, Xolair) had the desired characteristics, which included good tolerability, a reduction in free serum IgE to undetectable levels, inhibition of allergic reactions, a lack of mast cell degran-ulation (unlike polyclonal anti-IgE, which serves as a model to mimic allergic reactions), and a lack of immunogenicity (the latter the result of the 95% humanization) [16]. [source, 2005]